Archived NIH announcements

NIH implementation of Research Security Training requirements outlined in the CHIPS and Science Act of 2022 goes into effect for applications submitted for due dates on or after May 25, 2026.

Senior/key personnel listed on an NIH grant application must certify that they have completed the training within 12 months of the date of application submission. NIH does not collect Current and Pending (Other) Support at the time of application based on our Just-in-Time policy. Therefore, NIH will collect the individual certification at the time of the application submission, through the Biographical Sketch in SciENcv.

Read notice.

The NIH canceled more than 370 peer review meetings between Oct. 1 and Nov. 14. These meetings had enlisted more than 11,000 reviewers to review more than 24,000 applications.

To address the backlog of applications scheduled for peer review, the NIH is making the following emergency modifications to its review processes and policies that will remain in place through the May 2026 Advisory Council:

• Reducing the percentage of applications discussed in most meetings. This change will allow nearly all review meetings to run within one day and make recruiting reviewers and rescheduling meetings easier. Committees will vote for which applications to discuss in three groups:
  • The top third (30 to 35 percent) will be discussed in the review meeting and considered for funding.
  • The middle third will be designated as “competitive but not discussed” and considered for funding.
  • The lowest third will be designated as “not competitive and not discussed.”
     
• Simplifying summary statements, which will continue to provide the necessary information regarding applications’ scientific merit to advisory councils and program staff. Summary statements will have:
  • A sentence describing the degree of consensus in the committee vote.
  • Bullets describing the main score driving points.
  • Written critiques from the three assigned reviewers.
  • For discussed applications, the overall impact score.

Read news post.

The NIH posted information on how agency operations are resuming after the government shutdown, including:

• Rescheduled submission dates and peer review meetings.
• Instructions for post-submission materials, research performance progress reports and other areas.

Read notice.

The NIH is working to reschedule October and November deadlines for grant and contract submissions and dates for missed review meetings, training and other activities that were scheduled to occur during and immediately following the period of the government shutdown.

Read notice.

On Sept. 11, 2025, the NIH announced that research security training would be required in January 2026.

Today the NIH rescinded its notice in an effort to coordinate with the National Science Foundation and other federal research agencies and finalize guidance on each of the required elements outlined in the Office of Science and Technology Policy Guidelines for Research Security Programs at Covered Institutions, and to develop a centralized process for recipients to certify compliance. An implementation date has not been set.

Read notice.

The NIH has recognized that current application and award structures for subawards have failed to meet federal reporting and oversight needs. This has raised concerns for national security. To address these needs, NIH announced that it will no longer be accepting new applications that request funds for foreign components using the traditional grant subaward/consortium structure.

• Proposals with foreign components will be submitted to a new Notice of Funding Opportunity (NOFO).
• Proposals with foreign components will provide an:
  1. Overall component
  2. Research component
  3. International project component
• NIH is developing resources, including FAQs (coming soon). 

Read notice.

Beginning Jan. 25, 2026, the NIH will require principal investigators, co-investigators and other key personnel to complete annual research security training within the 12 months preceding the date a grant application is submitted.

Read notice.

NIH has re-enabled the no-cost extension functionality within eRA Commons. Recipients may resume initiating first no-cost extensions in eRA Commons.

Read notice.

Starting Oct. 1, 2025, NIH grant recipients must provide training for faculty and researchers identified as senior/key personnel on the agency's new policy requirement to disclose all research activities and affiliations (active and pending) in the "other support" section of grant applications. See other support form.

The Division of Research is developing plans to comply with this policy and will be communicating with the grants community.

Read notice.

The agency is providing guidance on the appropriate use of AI to in proposals to maintain the fairness and originality of the NIH research application process.

NIH also is instituting a new policy limiting the number of new, renewal, resubmission and revision applications that principal investigators can submit in a calendar year.

Read notice

The expansion is part of a broader initiative to prioritize human-based research and reduce reliance on animal models. Make sure to carefully read current and upcoming NIH funding opportunities for NAMs-related criteria. 

Guidance from Mizzou's Division of Research, Innovation and Impact

NIH issued a short-term extension to the early-stage investigator eligibility period.

This extension addresses delays impacting grant application submissions, peer review or award processing timelines between Jan. 1, 2025, and May 31, 2025, and seeks to mitigate their effects on the biomedical research community. 

Read notice.

Keep on top of the latest changes affecting NIH grants administration and funding by bookmarking this page, which is updated as new information becomes available.

NIH has removed the automatic no-cost extension (NCE) feature from their website. All NCEs must now be requested via the prior approval module. 

Read notice.

On May 5, 2025, the White House Executive Action on Biological Research directed federal agencies to end funding for “dangerous gain-of-function research” and develop a new oversight policy within 120 days. In response, the NIH released an updated notice on May 7, 2025, rescinding their previous DURC-PEPP policy implementation guidance. Other federal funding agencies have not yet published updated guidance. The DURC program oversees life sciences research that could be misused to harm public health or national security.

MU will continue to monitor developments and update the Institutional Biosafety Committee homepage as new information becomes available. 

NIH is updating its policy and practice on issuing foreign subawards. 

• The new policy will prohibit foreign subawards from being nested under the parent grant.
• This new award structure will allow NIH to track the project’s funds individually, while scientific progress will be reported collectively by the primary institution, under the Research Performance Progress Report.
• NIH anticipates implementing the new award structure by Sept. 30, 2025 (before fiscal year 2026).  

Effective May 1, 2025, and until the details of the new foreign collaboration award structure are released, NIH will not issue awards to domestic or foreign entities (new, renewal or non-competing continuation) that include a subaward to a foreign entity. 

Please note: PIs can eliminate the foreign subaward during this time, and funding will continue. 

Read notice.  |  Read article.

The U.S. Department of Health and Human Services and the NIH have announced a universal vaccine platform called Generation Gold Standard developed by NIH’s National Institute of Allergy and Infectious Diseases to create broad-spectrum vaccines targeting multiple pandemic-prone viruses like avian influenza (H5N1) and coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV). 

The initiative aims to improve pandemic preparedness and vaccine effectiveness by focusing on long-lasting, cross-strain protection, beyond current virus strains. Key components of this platform include: 

• BPL-inactivated whole-virus vaccines that preserve the virus's structure while preventing infectivity, generating strong immune responses (B and T cells), and offering protection across various virus families
• Intranasal formulation of the BPL-1357 vaccine, which is designed to block virus transmission and is currently in advanced clinical trials, on track for FDA review by 2029
• Increased government-led transparency and the elimination of commercial conflicts of interest  

The BPL platform could be adapted for future vaccines against other respiratory viruses. Clinical trials for universal influenza vaccines are set to begin in 2026, with FDA approval targeted for 2029.

Read announcement.

NIH announced the compliance date for the revised public access policy will move up by six months, from Dec. 31, 2025, to July 1, 2025. All other aspects of the 2024 public access policy remain the same. 

NIH Director Jay Bhbattacharya issued a statement detailing the benefits of the change.

Read notice.

Sponsored Programs Administration received communication from NIH requesting the early submission of Research Performance Progress Reports (RPPRs ) to allow for processing time of notice of awards. We encourage PIs to submit their RPPRs two months prior to the end date.

NIH announced its initiative to reduce the use of animals in NIH-funded research. This follows the FDA roadmap released in April, which discussed collaboration with the NIH.  

NIH Director Bhattacharya emphasized that innovations such as organoids, tissue chips and computational models allow for more accurate human-centric research, potentially improving health care outcomes and accelerating the development of treatments. 

As part of the initiative, the NIH will establish the Office of Research Innovation, Validation and Application (ORIVA) to oversee these efforts. ORIVA will focus on promoting non-animal research methods, increasing funding, and ensuring their integration into NIH's broader biomedical research programs.  

Read announcement.

NIH issued a notice that fund recipients must comply with all applicable federal anti-discrimination laws material to the government’s payment decisions. This term applies prospectively to new, renewal, supplement or continuation awards issued on or after April 21, 2025. 

By accepting grant awards, recipients certify that: 

• They do not, and will not during the term of the financial assistance award, operate any programs that advance or promote DEI, DEIA or discriminatory equity ideology in violation of federal anti-discrimination laws.
• They do not engage in and will not, during the term of the award, engage in a discriminatory prohibited boycott, as defined in the notice.  

The NIH reserves the right to terminate financial assistance awards and recover all funds if recipients operate any program that violates federal anti-discriminatory laws or engage in a prohibited boycott. 

Note: The notice applies only to grant award “recipients,” which the NIH defines as the entity that receives the NIH grant award. 

Read notice.